Anaveon
Latest round
- Series B
Last raised
- Dec 2021
Total raised
- $154M
Investors
- 6
About Anaveon
Founded in 2017 in Basel, Switzerland, Anaveon AG specializes in immunotherapy development. The company has undergone strategic evolution, focusing on pioneering cancer treatment innovations.Anaveon AG specializes in the development of innovative immunotherapies aimed at addressing significant medical needs in oncology and autoimmune diseases. The company's core product offerings include ANV419, a lead immunotherapy candidate designed specifically for cancer treatment, which entered clinical trials in 2021, and ANV600, a bispecific molecule initiated into first-in-human trials in 2024. These compounds aim to orchestrate immune responses through advanced protein engineering, targeting high unmet needs in patient populations. Anaveon's products are primarily directed towards healthcare providers and institutions globally, including markets in Europe and North America, with a focus on oncology clinics, academic research centers, and specialized healthcare facilities. The company's revenue model is built upon partnerships with healthcare providers and research institutions for clinical trials and product development, as well as potential future sales of its proprietary therapies once they receive regulatory approval. Transactions typically occur through structured agreements with pharmaceutical partners, characterized by milestone payments and profit-sharing arrangements associated with the development and commercialization of its flagship products, such as ANV419 and ANV600. The company aims to enhance its product offerings and is focusing on expanding into new markets across Europe and North America. The strategic utilization of recent funds will support these initiatives, facilitating advancements in immunotherapy and addressing broader healthcare needs.
Who invested in Anaveon
6 investors across 2 rounds
See all investors in Anaveon
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Anaveon
Who invested in Anaveon?
Anaveon has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Anaveon raised?
Anaveon has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Anaveon last raise money?
Anaveon's most recent round on record is a Series B, in Dec 2021.
What does Anaveon do?
Founded in 2017 in Basel, Switzerland, Anaveon AG specializes in immunotherapy development.
Where is Anaveon headquartered?
Anaveon is headquartered in Basel, Switzerland.
Which VCs invest in companies like Anaveon?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Anaveon's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Anaveon? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.